Welcome to Pharmaxis
Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.
Founded on an Australian discovery, Pharmaxis' products are now available worldwide.
Phase 1 clinical trial for SSAO/VAP-1 inhibitor commences
Pharmaxis today announced that it has commenced a Phase 1 clinical trial of its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor (PXS4728A) investigating its potential to treat inflammatory diseases.
Phase 3 clinical trial in cystic fibrosis begins
Pharmaxis has enrolled the first subject in its international clinical trial evaluating Bronchitol® in adults with cystic fibrosis (CF303).
Significant business milestones: Commercialisation of Bronchitol (Mannitol) in USA, Novaquest dispute settled
Pharmaxis announced it has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) in the United States.
Pharmaxis signs agreement with Boehringer Ingelheim for SSA Inhibitor PXS4728A
Pharmaxis has announced it has signed an Option and Asset Purchase Agreement with Boehringer Ingelheim for the SSAO Inhibitor PXS4728A.
LATEST NEWS & PUBLICATIONS